Zenopharm, a Xavier University spin-out led by Dr. Guangdi Wang, was recently awarded a $2 Million SBIR Phase II Grant from the National Cancer Institute. Zenopharm was founded in 2012 to commercialize improved endocrine therapeutics for breast cancer, based on the Company’s patent-pending high-bioavailability platform technology. Zenopharm has developed four oncology drug candidates for treatment of hormone receptor positive breast cancer, which are at various preclinical development stages. The SBIR process is very competitive, and Dr. Wang’s success is a great example of the high-quality research being done in Louisiana.